All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Exempt | 2007-002557-23 | A Phase I/II Open-Label Dose Escalation Study to Investigate the Safety and Tolerability of Acadesine in Patients with B-Cell Chronic Lymphocytic Leukaemia | not-yet-due | |
Reported results | 2008-000912-34 | A PHASE 2 STUDY OF THE ANTI-TUMOUR ACTIVITY AND SAFETY OF PROLARIX™ IN HEPATOCELLULAR CARCINOMA (HCC) | 2009-09-01 | due-trials |
Not reported Terminated | 2008-001001-41 | A Randomized, Double Blind, Placebo Controlled Study of the Efficacy and Safety of Angiotensin Therapeutic Vaccine (ATV) in Patients With Mild to Moderate Hypertension | 2009-06-01 | due-trials |
Reported results Terminated | 2008-003659-63 | A multicentre double-blind, placebo-controlled, randomised, parallel-group study to evaluate the safety and efficacy of BGC20-1259 in patients with mild to moderate probable Alzheimer’s Disease. | 2009-02-06 | due-trials |
Reported results Terminated | 2009-010862-43 | A multinational, multi-centre, randomised, double-blind, placebo-controlled, 3-way crossover study in migraine patients, treated with two doses of BGC20-1531 and placebo. | 2010-06-30 | due-trials |
Listed as ongoing, but also has a completion date | 2009-011585-28 | A randomised double-blind placebo-controlled phase IIa study of orally administered BGC20-0134 in patients with relapsing-remitting multiple sclerosis (RRMS) | 2011-10-05 | bad-data |